Journal of Neuro-Oncology

, Volume 111, Issue 1, pp 19–23 | Cite as

Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma

  • Kevin Petrecca
  • Marie-Christine Guiot
  • Valerie Panet-Raymond
  • Luis Souhami
Clinical Study


Glioblastomas (GBM) are highly motile cancers that invade through normal brain. In the absence of curative chemotherapy this invasion, beyond surgical and radiotherapy margins, to distant brain sites is thought to be an important cause of treatment failure. Paradoxically, studies analyzing failure patterns have consistently shown that the large majority of failures occur at the original tumor site. This conflict may be explained by the fact these cancers are often only sub-totally resected and radiotherapy and chemotherapies fail to control this significant local cancer burden. We analyzed the failure pattern in 20 consecutive patients with complete resection of the gadolinium-enhancing portion of GBM demonstrated on the immediate post-operative magnetic resonance study, and who underwent a radical course of radiotherapy and chemotherapy. We found that recurrences occurred only at the resection margin in 17 of 20 patients. Recurrences were exclusively distant in 2 of 20 patients and occurred at both the resection margin and a distant site in 1 of 20 cases. We found that even in cases of complete resection of the gadolinium-enhancing portion of GBM 85 % of recurrences are localized to the resection margin.


Glioblastoma Gliomas Brain cancer Gliomas surgery Recurrence Failure 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Demuth T, Berens ME (2004) Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 70:217–228PubMedCrossRefGoogle Scholar
  2. 2.
    Chamberlain MC (2007) Radiographic patterns of relapse in glioblastoma. J Neurooncol 101:319–323CrossRefGoogle Scholar
  3. 3.
    Dobelbower MC, Burnet OL III, Nordal RA, Nabors LB, Markert JM, Hyatt MD, Fiveash JB (2011) Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol 55:77–81PubMedCrossRefGoogle Scholar
  4. 4.
    McDonald MW, Shu HKS, Curran WJ Jr, Crocker IR (2011) Pattern of failure after limited radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 79:130–136PubMedCrossRefGoogle Scholar
  5. 5.
    Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella R, Enrici RM (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97:377–381PubMedCrossRefGoogle Scholar
  6. 6.
    Oh J, Sahgal A, Sanghera P, Tsao MN, Davey P, Lam L, Symons S, Aviv R, Perry JR (2011) Gliobastoma: patterns of recurrence and efficacy of salvage treatments. Can J Neurol Sci 38:621–625PubMedGoogle Scholar
  7. 7.
    Mercier L, Del Maestro RF, Petrecca K, Kochanowska A, Drouin S, Yan CX, Janke AL, Chen SJ, Collins DL (2011) New prototype neuronavigation system based on preoperative imaging and intraoperative freehand ultrasound: system description and validation. Int J Comput Assist Radiol Surg 6:507–522PubMedCrossRefGoogle Scholar
  8. 8.
    Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Van den Bent MJ, Change SM (2012) Application of novel response/progression measures for surgically delivered therapies for Gliomas: response assessment in neuro-oncology RANO (working group). Neurosurgery 70:234–244PubMedCrossRefGoogle Scholar
  9. 9.
    Wen PY, Macdonal DR, Reardon DA, Cloughesy TF, Sorenson AG, Galanis E, DeFroot J, Wick W, Gilber MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, Van Den Bent MJ, Chang SM (2010) Updated response assessment criteria for high grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972PubMedCrossRefGoogle Scholar
  10. 10.
    Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, Oulad Ben Taib N, Rorive S, David P, Brotchi J, Levivier M (2006) Integrated positron emission tomography and magnetic resonance imaging–guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 104:238–253PubMedCrossRefGoogle Scholar
  11. 11.
    Pirotte BJM, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorive S, David P, Brotchi J (2009) Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 64:471–481PubMedCrossRefGoogle Scholar
  12. 12.
    Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401PubMedCrossRefGoogle Scholar
  13. 13.
    Stummer W, Novotny A, Stepp H, Goetz C, Bise K (2000) Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93:1003–1013PubMedCrossRefGoogle Scholar
  14. 14.
    Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncol 5:79–88Google Scholar
  15. 15.
    Pan E, Mitchell SB, Tsai JS (2008) A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 88:353–3577PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Kevin Petrecca
    • 1
  • Marie-Christine Guiot
    • 2
  • Valerie Panet-Raymond
    • 3
  • Luis Souhami
    • 3
  1. 1.Department of Neurology and NeurosurgeryMontreal Neurological Institute and Hospital, McGill UniversityMontrealCanada
  2. 2.Department of PathologyMontreal Neurological Institute and Hospital, McGill UniversityMontrealCanada
  3. 3.Department of Radiation OncologyMcGill University Health CentreMontrealCanada

Personalised recommendations